Hemab Therapeutics/X
Aug 13, 2025, 09:21
VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
Hemab Therapeutics shared an inviting post on X:
”Now enrolling people living with Type 1 Von Willebrand disease (VWD) into the VELORA Discover study.
This observational study aims to deepen understanding of Type 1 VWD and help lay the groundwork for future advances in care.
If you are living with Type 1 VWD or treating people who are, learn more about how to participate.”
You can direct your inquiries to [email protected].
Stay informed on all opportunities in the field of bleeding disorders with Hemostasis Today.
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia
-
Apr 5, 2026, 17:41Gevorg Yaghjyan: Attending an AI Conference on AI in Clinical Medicine, Research and Education
-
Apr 5, 2026, 17:41Ifeanyichukwu Ifechidere: The Mastermind of Clotting – A Thrombin Story
-
Apr 5, 2026, 17:38Thomas Ichim: Making iPSC Cells from Menstrual Blood Stem Cells